Alector Stock Price, News & Analysis (NASDAQ:ALEC)

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ALEC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALEC, but not buy additional shares or sell existing shares.
View ALEC analyst ratings or view top-rated stocks.

9 Wall Street research analysts have issued 1-year target prices for Alector's stock. Their ALEC share price targets range from $4.00 to $41.00. On average, they anticipate the company's stock price to reach $13.70 in the next twelve months. This suggests a possible upside of 143.8% from the stock's current price.
View analysts price targets for ALEC or view top-rated stocks among Wall Street analysts.

Alector's stock was trading at $9.23 at the beginning of the year. Since then, ALEC stock has decreased by 39.1% and is now trading at $5.62.
View the best growth stocks for 2023 here.

Alector saw a decline in short interest in November. As of November 15th, there was short interest totaling 7,150,000 shares, a decline of 6.9% from the October 31st total of 7,680,000 shares. Based on an average trading volume of 717,100 shares, the short-interest ratio is presently 10.0 days. Approximately 11.7% of the company's stock are sold short.
View Alector's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our ALEC earnings forecast.

Alector, Inc. (NASDAQ:ALEC) issued its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.12. The business had revenue of $9.11 million for the quarter, compared to analyst estimates of $9 million. Alector had a negative trailing twelve-month return on equity of 74.78% and a negative net margin of 146.80%.

iShares Neuroscience and Healthcare ETF holds 7,557 shares of ALEC stock, representing 1.22% of its portfolio.

4 employees have rated Alector Chief Executive Officer Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among the company's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO).

(ALEC) raised $177 million in an IPO on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO.

Alector's stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (14.47%), Braidwell LP (4.84%), Morgan Stanley (3.97%), JPMorgan Chase & Co. (2.72%), Euclidean Capital LLC (1.55%) and Jacobs Levy Equity Management Inc. (0.92%). Insiders that own company stock include Arnon Rosenthal, Calvin Yu, Gary Romano, Marc Grasso, Polaris Venture Management Co, Richard H Scheller, Robert King, Robert Paul, Sara Kenkare-Mitra and Shehnaaz Suliman.
View institutional ownership trends.

Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.